Rigel Pharmaceuticals Inc. (New)

RIGL Stock Report Card

Today's performance

50%

Performance

Score:

100/100

RIGL returned -0.79% in the last 12 months. Based on SPY's performance of -8.74%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

Score:

83/100

3 analysts offer 12-month price targets for RIGL. Together, they have an average target of 1.5, the most optimistic target put RIGL at 2 within 12-months and the most pessimistic has RIGL at 1. These analyst ratings are from our partners at Financial Modeling Prep (https://site.financialmodelingprep.com/) and Alpha Vantage (https://www.alphavantage.co/).

Sentiment

Score:

69/100

RIGL had a bullish sentiment score of 68.96% across Twitter and StockTwits over the last 12 months. It had an average of 30.16 posts, 22.27 comments, and 108.56 likes per day.

Technicals

Score:

11/100

RIGL receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

Score:

43/100

RIGL has missed earnings 3 times in the last 20 quarters.

Profit

Score:

18/100

Out of the last 20 quarters, RIGL has had 4 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

Score:

48/100

RIGL has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

Rigel Pharmaceuticals Inc. (New) Summary

Nasdaq / RIGL

Healthcare

Biotechnology

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Pluto is a technology provider that provides you with information, software, and automation tools for the purpose of investment education, but it does not make investment recommendations of securities, investment strategies, or account types, either in general or individualized for you or any other subscriber. If you want to receive individualized investment advice, you should consult with your own financial adviser. Pluto also does not provide you with legal, tax, or accounting advice. You agree that you understand that Pluto is not an investment adviser or a broker-dealer and does not have a fiduciary duty to you or a duty to act in your best interests. Pluto can help you back-test the historical performance of strategies that you create, but it does not recommend strategies and reminds you that the historical performance of a strategy is not a reliable predictor of future results for that strategy. Pluto uses third-party information, for example, about securities market data, that it reasonably believes to be reliable, but it does not warrant that the information is complete, accurate, or up-to-date, and as discussed further below, Pluto does not provide any warranty of merchantability or warranty for a particular purpose for that third-party market data or other information. Investing involves risk, including the risk of loss, and you should not use the Pluto technology in connection with investments unless you are able to and intend to evaluate the technology and the risks and make your own self-directed investment decisions.

Power up your portfolio

Build a portfolio of your favorite stocks

Pluto makes it easy to build investing strategies and automate your portfolio

See how

Checkout Similar Companies

RIGL scored highly on our reportcard. Here are some similar companies and how they performed.

Merck & Co., Inc.

$MRK Stock Report Card

ABBVIE INC.

$ABBV Stock Report Card

Innate Pharma S.A. ADS

$IPHA Stock Report Card

Fulcrum Therapeutics, Inc. Common Stock

$FULC Stock Report Card

Talkspace, Inc. Common Stock

$TALK Stock Report Card

Bioventus Inc. Class A Common Stock

$BVS Stock Report Card

Sangamo Therapeutics, Inc. Common Stock

$SGMO Stock Report Card

Burning Rock Biotech Limited American Depositary Shares

$BNR Stock Report Card

View all stock report cards

Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.